Max Healthcare Institute to Approve September Results Today

Max Healthcare Institute will consider and approve its unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026, at a board meeting on October 30. The latest reported June-quarter consolidated revenue was ₹2,366 crore, while net profit was ₹323 crore.

When will Max Healthcare announce its September 2026 results?

Max Healthcare will consider its September 2026 quarter results at a board meeting scheduled for Friday, October 30, 2026. The company informed the stock exchanges on October 23 that its board would consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.

The September quarter is identified as Q2 FY27 in the company-result calendar provided. At the time of the board meeting, the results were not yet available on the NSE. The company’s exchange filing is the relevant confirmation for both the meeting date and the scope of the financial statements under consideration.

The announcement follows the closure of Max Healthcare’s trading window from October 1. The window will remain closed until 48 hours after the declaration of the unaudited results, in line with the company’s code of conduct and the SEBI (Prohibition of Insider Trading) Regulations, 2015.

The company had previously reported its Q1 FY27 earnings on August 13, 2026. That June-quarter performance is the latest reported financial baseline available before the September-quarter board meeting.

What did Max Healthcare report in the June 2026 quarter?

Max Healthcare reported consolidated revenue of ₹2,366 crore for the June 2026 quarter, up 17% year on year and 10.42% sequentially from ₹2,143 crore in March 2026. EBITDA was ₹598 crore, compared with ₹523 crore a year earlier and ₹606 crore in the preceding quarter.

Net profit for the quarter stood at ₹323 crore, up 5% from ₹308 crore in June 2025 but lower than ₹342 crore in March 2026. Earnings per share were ₹3.32, compared with ₹3.17 in June 2025 and ₹3.52 in March 2026.

The June-quarter operating margin was 25.27%, based on operating profit of ₹598 crore and sales of ₹2,366 crore. This was below the 28% operating margin reported in March 2026, while still remaining within the 25% to 28% range seen in the recent quarterly data.

How has Max Healthcare's quarterly revenue trend developed?

Max Healthcare’s reported sales rose from ₹2,028 crore in June 2025 to ₹2,366 crore in June 2026, marking a steady increase across the five reported quarters in between. Sales were ₹2,135 crore in September 2025, ₹2,068 crore in December 2025 and ₹2,143 crore in March 2026 before reaching the June-quarter level.

Operating profit over the same period moved from ₹523 crore in June 2025 to ₹575 crore in September 2025, ₹538 crore in December 2025, ₹606 crore in March 2026 and ₹598 crore in June 2026. The margin ranged from 25% to 28%, showing that profit growth did not move in a straight line alongside revenue.

The September 2025 quarter provides the year-earlier reference point for the results now due. The supplied historical data lists sales of ₹2,135 crore, operating profit of ₹575 crore and operating margin of 27% for that quarter. It also notes that the September 2025 net profit of ₹491 crore included a tax-related one-off, which affects direct comparison with later reported profit figures.

What other developments are relevant before the results?

Max Healthcare opened a 400-bed tower at Max Smart Super Speciality Hospital in Saket in September 2026. The expansion adds hospital capacity and is relevant to the company’s operating footprint, although the provided information does not state its financial contribution to the September-quarter results.

The company also participated in investor engagement activities during September, including the J.P. Morgan investor conference on September 21 and the Jefferies India Forum on September 16. These events provided meetings with investors, but the available disclosures did not indicate fresh financial guidance.

On September 19, shareholders approved four special resolutions through a postal ballot. Earlier that month, the company approved the allotment of 33,765 ESOP shares. The disclosure described the resulting increase in share capital as not material to shareholders.

A separate matter involved litigation concerning Kalinga Hospital Ltd. The NCLT had directed respondents to file replies, and a hearing was adjourned to October 29, 2026. The supplied updates do not provide a final outcome, so the board results remain the next confirmed corporate event for investors.

How are investors assessing Max Healthcare before the announcement?

Investors will be able to compare the September-quarter revenue and margin trend with the June quarter, when revenue reached ₹2,366 crore but operating margin declined to 25.27% from 28% in March 2026. Reported net profit growth in June was also slower than revenue growth, at 5% year on year versus 17% for sales.

The available market updates show that Max Healthcare’s shares closed at ₹929.70 on September 29, down 5.51% the following day, in connection with the adjournment of the KHL litigation hearing. The share price had closed at ₹1,000.90 after the September 25 update on the trading-window closure. These are event-linked next-day price movements cited in the provided data, not evidence of a sustained market trend.

For the trailing twelve months ended FY26, the supplied information states that revenue from operations rose 19.14% to ₹8,373.45 crore and net profit increased 34.07% to ₹1,442.41 crore. Operating cash flow was ₹1,633.32 crore in FY26, compared with ₹1,459.31 crore in FY25. These figures provide a broader financial context, while the September-quarter filing will provide the next reported update on current operations.

Conclusion

Max Healthcare’s October 30 board meeting is the confirmed date for consideration of its September 2026 quarter and half-year financial results. The latest reported June quarter showed revenue of ₹2,366 crore, but EBITDA and net profit were lower than in the immediately preceding March quarter, making the next margin and profit figures important points of comparison.

Investors should watch for the company’s exchange filing after the board meeting, including the reported September-quarter revenue, profitability and any commentary in the unaudited standalone and consolidated results. The trading window is scheduled to reopen 48 hours after the results are declared, while the Kalinga Hospital litigation matter remains unresolved in the information provided.